SPOTLIGHT -
Patients Prefer Subcutaneous Regimen for HER2-Positive Breast Cancer
Andrew Seidman, MD, discusses the PHranceSCa trial of patient preference for intravenous versus subcutaneous trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer.